ABOUT US
Gene and Cell therapy pioneer and leader
Long-term focus on the development and translation of gene engineering technology applications such as tumor-targeted drug gene therapy and cell therapy.
1
7.5
K+
Customer
60
+
Researchers
70
Employee
30
+
Patent
Our Products
Clinical-grade gene and cell therapy products
Pipeline progress
With gene therapy and cell therapy As the core
Doublle Bio has established a product matrix centered on gene therapy and cell therapy, covering multiple clinical stages, and has formed a sustainable development pipeline for a series of innovative anti-tumor drugs
E10A（Recombinant human endostatin adenovirus injection ）
Phase III trial
E10H（Autologous Natural Killer Cell Injection）
Phase II trial
E10I（Umbilical cord mesenchymal stem cell injection）
Phase I trial
services
Our advantageous
The company has long been dedicated to the development and translation of gene engineering technology applications, including targeted tumor drug gene therapy and cell therapy. It holds over 30 patents in various fields.
Our Team
Our Professional Team
We are a skilled, tightly knit professional team. United by shared goals, we bring focus, resilience, and expertise to every challenge we face.
Huang Wenlin
Chairman & Chief Scientist
Tian Shuo
CEO
Zhai Liutao
Deputy General Manager
Wang Jian
Deputy General Manager
Contact Us
Obtain better assistance and services
Latest News
Track our progress in real-time
Enrollment Completed for Doublle Bio hUC-MSCs
The enrollment of the low-dose group in the Phase I clinical trial of Dabao Biological Human Umbilical
Read More
[Patient Recruitment] Clinical Recruitment for
Phase I clinical study on the safety, tolerability, and preliminary efficacy of E10I stem cell therapy for
Read More
GuangZhou Doublle Biotech successfully passed the
The Biological Testing Center of Guangzhou Doublle Biological Products Co., Ltd. has successfully passed the regular supervision
Read More